Could Ozempic-Like Drugs Help Prevent Breast Cancer? Study Sparks Hope

Popular

weight loss drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound may offer benefits beyond weight loss and diabetes control. A new study suggests that women taking GLP-1 medications could have a significantly lower risk of developing breast cancer, adding to growing scientific interest around the broader health effects of these drugs. The findings were presented at the American Society of Clinical Oncology Annual Meeting and published in JCO Oncology Practice.Also read: A Robotic Kidney Transplant And A Mother’s Gift Helped Save A 31-Year-Old Man

What did the study find?

Researchers from the University of Pennsylvania Perelman School of Medicine analyzed health records from more than 110,000 women between the ages of 45 and 80. The team compared women using GLP-1 medications with women who were not taking these drugs. The results showed that women using GLP-1 medications were approximately 30% less likely to develop breast cancer compared to non-users. Importantly, the reduced risk remained even after researchers adjusted for multiple factors, including:

• Age
• Race and ethnicity
• Body mass index (BMI)
• Breast density
• Diabetes status

Experts say the findings add to a growing body of evidence suggesting these medications may have cancer-related benefits worth investigating further.

What are GLP-1 drugs?

GLP-1 receptor agonists are medications that mimic a natural hormone called glucagon-like peptide-1. This hormone helps regulate appetite, blood sugar, insulin release, and digestion. Originally developed for type 2 diabetes treatment, GLP-1 drugs have become widely known for helping people achieve significant weight loss. These medications are now commonly prescribed for obesity management and metabolic health improvement.

Why could GLP-1 drugs lower breast cancer risk?

Researchers believe several factors may explain the connection.

Weight loss and reduced obesity risk

Obesity is a major risk factor for breast cancer, particularly after menopause. Excess body fat can increase inflammation, hormone imbalance, and insulin resistance, all of which may contribute to cancer development. By helping people lose weight and improve metabolic health, GLP-1 medications may indirectly lower cancer risk.

Anti-inflammatory effects

Scientists also point to the anti-inflammatory properties of GLP-1 drugs. Chronic inflammation has long been associated with the development and progression of several cancers, including breast cancer. Reducing inflammation may create an environment less favorable for tumour growth.

Improved insulin sensitivity

High insulin levels and insulin resistance are linked to increased cancer risk. GLP-1 medications improve insulin sensitivity and blood sugar regulation, which may also contribute to lower cancer risk.

Why experts are still cautious

Despite the encouraging findings, researchers stress that the study was observational. This means the research identified an association between GLP-1 use and lower breast cancer rates, but did not prove that the medications directly prevent cancer. Other lifestyle or healthcare-related factors may also have influenced the results. Experts say randomized clinical trials are now needed to confirm whether GLP-1 medications can truly play a role in breast cancer prevention. Scientists are increasingly studying GLP-1 drugs beyond diabetes and weight loss treatment. Recent research has explored their potential benefits in cardiovascular disease, kidney disease, inflammation, and cancer prevention. As obesity-related cancers continue to rise worldwide, researchers hope therapies that improve metabolic health may eventually become part of broader cancer prevention strategies. While more evidence is still needed, the new findings suggest GLP-1 medications could someday reshape not only obesity care but also preventive medicine.